Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02598440 · ClinicalTrials.gov registry record · Phase 4
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Phase 4 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 4
- Development phase
- 341
- Enrollment target
NCT02598440: Completed Phase 4 study, sponsored by Hoffmann-La Roche.
NCT02598440 is a Phase 4 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 341 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02598440, a Phase 4 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 341 participants
- Enrollment target
Study Summary
This study will evaluate participant-reported preference for either ibandronate or a comparator drug in women with postmenopausal osteoporosis. The anticipated time of study treatment is 6 months, and the target sample size is 338 individuals.
Interventions
- DRUG Alendronate
- DRUG Ibandronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 341 participants |
| Start Date | 2004-03 |
| Est. Completion | 2005-05 |
| Phase | Phase 4 |
What the finished NCT02598440 record still lists
NCT02598440 is an interventional study that assigns participants to a tested intervention. The registered 341 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (34% lower).
The record links to 0 conditions, and to 2 interventions - of which Alendronate is the first listed.
NCT02598440 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02598440 about?
NCT02598440 is a clinical study titled "A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis". This study will evaluate participant-reported preference for either ibandronate or a comparator drug in women with postmenopausal osteoporosis. The anticipated time of study treatment is 6 months, and the target sample size is 338 individuals.
What is the current status of trial NCT02598440?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 341 participants. The study started on 2004-03. Estimated completion is 2005-05.
What interventions are being tested in trial NCT02598440?
The interventions under investigation include: Alendronate (DRUG), Ibandronate (DRUG).
Who is sponsoring clinical trial NCT02598440?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02598440's enrollment target sits among peer trials
341 246th of 2000 higher than 1,755 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06852170 · 341 participants · NA
Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention
- NCT05283850 · 342 participants · Phase 2
Surviving PEA in Roanoke (SPEAR) Study
- NCT05714085 · 342 participants · Phase 2
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
- NCT06188702 · 342 participants · Phase 1
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia